Relief enters definitive agreement with Meta Healthcare to acquire US FDA approved novel dosage form of aprescription drug to treat PKU

Relief Therapeutics Holding SA, a biopharmaceutical company, announced that its wholly owned subsidiary, APR Applied Pharma Research SA (APR), has executed a definitive agreement with Meta Healthcare Ltd. (Meta), acquiring the worldwide rights, except for the United Kingdom (UK), for a novel dosage form of a prescription drug already approved by the US Food and Drug Administration (FDA) and intended for the treatment of patients with phenylketonuria (PKU). This improved product is expected to improve patient acceptance and compliance. Financial terms of the agreement were not disclosed. As previously announced, under the terms of the agreement, Meta will provide the technology transfer package and Relief will conduct clinical studies, manufacturing, regulatory submission and commercialization in the US and EU.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!